Kushikata, Tetsuya, Takeshi Kubota, Jidong Fang, and James M. Krueger. Glial cell line-derived neurotrophic factor promotes sleep in rats and rabbits. Am J Physiol Regulatory Integrative Comp Physiol 280: R1001-R1006, 2001.-Various growth factors (e.g., growth hormone-releasing hormone, acidic fibroblast growth factor, nerve growth factor, brain-derived neurotrophic factor, and interleukin-1) are implicated in sleep regulation. It is hypothesized that neuronal activity enhances the production of such growth factors, and they in turn form part of the sleep regulatory mechanism. Glial cell line-derived neurotrophic factor (GDNF) promotes development, differentiation, maintenance, and regeneration of neurons, and its production is induced by well-characterized sleep regulatory substances such as interleukin-1 and tumor necrosis factor. Therefore, we investigated whether GDNF would promote sleep. Twenty-six male Sprague-Dawley rats and 30 male New Zealand White rabbits were surgically implanted with electroencephalogram (EEG) and electromyogram (EMG; rats only) electrodes, a brain thermistor, and a lateral intracerebroventricular cannula. The animals were injected intracerebroventricularly with pyrogen-free saline and on a separate day with one of the following doses of GDNF: 5, 50, and 500 ng in rabbits and 50 and 500 ng in rats. The EEG, brain temperature, EMG (in rats), and motor activity (in rabbits) were recorded for 23 h after the intracerebroventricular injection. GDNF (500-ng dose) increased the time spent in nonrapid eye movement sleep in both rats and rabbits. Rapid eye movement sleep was not affected by the lower doses of GDNF but was inhibited in rabbits after the high dose. EEG slow-wave activity was not affected by GDNF. The current results provide further evidence that various growth factors are involved in sleep regulation.
(GHRH, NGF, and BDNF). Inhibition of GH, IL-1, TNF, NGF, and GHRH inhibits spontaneous sleep and, in the case of GHRH, IL-1, and TNF, sleep rebound after sleep deprivation. These and much additional data strongly suggest that these growth factors are involved in physiological sleep regulation (18) (19) (20) and reviewed in Refs. 13 and 14) .
Glial cell line-derived neurotrophic factor (GDNF) is another cytokine that has the ability to promote the growth and survival of neurons (6 and reviewed in Ref. 5) . GDNF, along with neurturin, persephin, and artemin, are members of the transforming growth factor-␤ family. These molecules signal through a family of receptors [GDNF family ligands receptor-␣ (GFR␣) 1, 2, 3, and 4]. GFR␣-1 preferentially binds GDNF and is found on neurons in many areas of the brain (3, 22) . The GDNF promoter contains a nuclear factor-B (NF-B) site (38) ; NF-B also regulates the expression of many other sleep regulatory substances (reviewed in Ref. 15 ). Other sleep regulatory substances, such as IL-1 and TNF, have the capacity to enhance GDNF release and GDNF mRNA levels (36 and 37 and reviewed in Ref. 1) . We thus thought it likely that GDNF would promote sleep; we report here that GDNF enhances sleep in rats and rabbits.
MATERIALS AND METHODS
Recombinant human GDNF and recombinant rat GDNF were purchased from R&D systems (Minneapolis, MN). The bioactivity of the GDNF (i.e., its ability to support the survival of and stimulate neurite outgrowth of cultured embryonic chick dorsal root ganglia) was determined by the manufacturer. It contained 250 g BSA/5 g GDNF. Substances were dissolved in pyrogen-free isotonic saline (PFS; Abbott, North Chicago, IL). Injection volumes were 4 l for rats and 25 l for rabbits.
Animals. Male Sprague-Dawley rats (340-400 g) and male New Zealand White rabbits (4.5-5.5 kg) were surgically implanted with electroencephalogram (EEG) electrodes, a brain thermistor, a lateral intracerebroventricular cannula, and electromyogram (EMG) electrodes (only in rats) using ketamine-xylazine (35 and 5 mg/kg) anesthesia as previously described (11) . In rats, the patency and free drainage of the guide cannula were verified by injecting 40 ng of ANG II (Sigma, St. Louis, MO) in 4 l of PFS. If the cannula place-ment was correct, ANG II elicited a drinking response (31) . Only rats with a positive drinking response were used. After a 1-to 2-wk recovery period, the animals were placed in sleep-recording chambers (model 352600; Hot Pack, Philadelphia, PA). The rats were habituated to the recording procedure for 3 days; during this period, the rats were connected to recording cables and injected daily with PFS at the same time as the experimental treatments were to be done. The rabbits were habituated to the recording chamber for 1 day. The animals were kept on a 12:12-h light-dark cycle (lights on at 0800 with the rats or at 0600 with the rabbits) at 21 Ϯ 1°C ambient temperature. Water and food were available ad libitum throughout the experiment. A flexible tether connected the electrodes and thermistor leads to an electronic swivel. The animals were allowed relatively unrestricted movement inside the recording cages. EEG, brain temperature (T br ), motor activity detected by an ultrasonic sensor (only in rabbits; Biomedical Instrumentation, University of Tennessee), and EMG (only in rats) were recorded. The EEG was filtered below 0.1 and above 35 Hz. The amplified signals were digitized at a frequency of 128 Hz for the EEG and EMG and at 2 Hz for T br and motor activity. T br data were saved on a computer in 10-s intervals. T br values, averaged in 3-h intervals, were used for statistical analysis. Some of the T br data were lost because of technical problems; therefore, the sample sizes for T br were lower than those for sleep data.
On-line Fourier analyses of EEG data were performed. The vigilance states were determined off-line in 10-s epochs. The vigilance states of wakefulness, NREMS, and REMS were visually identified in 10-s epochs applying criteria previously reported (18) . The amount of time spent in each vigilance state was calculated for 1-h intervals and for the entire recording period. The percent of time spent in sleep for 3-h intervals was used for statistical analyses. The EEG power density values were summed in the delta (0.5-4.0 Hz) band, and then average delta activity during NREMS [also called slow-wave activity (SWA)] was calculated for 1-h time blocks. Because the EEG amplitude was subject to the influence of subtle variations of EEG electrode placement, the average power during NREMS throughout the entire 23-h control recording period was normalized to 100%. The relative changes in EEG power density values from the baseline were then calculated. In addition, a computer program was used to determine the number of NREMS and REMS episodes and their mean episode lengths, with the criterion that each episode lasted at least 30 s.
Experimental protocol. Twenty-six rats and 30 rabbits were used in these experiments. Each rat received an injection of 4 l PFS intracerebroventricularly to obtain control values. On a separate day, the same animals were then injected intracerebroventricularly with one of two doses of GDNF as follows: group 1, 50 ng (n ϭ 6); group 2, 500 ng (n ϭ 7). The injections took place on the dark onset (2000). In addition, seven rats were injected intracerebroventricularly with 500 ng GDNF at light onset (0800). Each rabbit received 25 l PFS intracerebroventricularly in the same manner as rats. On the next day, the animals were injected intracerebroventricularly with one of three doses of GDNF as follows: group 1, 5 ng (n ϭ 6); group 2, 50 ng (n ϭ 8); group 3, 500 ng (n ϭ 8). The injections took place between 0850 and 0925. As an additional control to exclude the effects of contaminants such as endotoxin, six rats and eight rabbits were injected intracerebroventricularly with 500 ng of heat-treated (90°C for 30 min) GDNF.
All statistical analyses were performed with two-way ANOVA for repeated measures across the entire recording period. A significance level of P Ͻ 0.05 was accepted.
RESULTS
Rats given heat-treated GDNF or physiological saline continued to exhibit the normal diurnal variations of sleep and T br that are characteristic of this species.
The lower dose of GDNF tested in rats (50 ng) at dark onset (2000) also failed to affect any of the parameters measured in this study. Administration of the higher dose of GDNF (500 ng) at dark onset increased the amount of time spent in NREMS [ANOVA; treatment effect; F(1,6) ϭ 13.16; P Ͻ 0.05; Fig. 1 and Table 1 ]. The (Tables 1 and 2 ) and also failed to affect EEG SWA after any dose. The higher dose of GDNF at dark onset slightly increased T br [ANOVA; treatment effect; F(1,6) ϭ 7.61; P Ͻ 0.05].
Heat-treated GDNF or physiological saline failed to alter the normal diurnal variations of sleep in rabbits (Fig. 2) .
Intracerebroventricular administration of the lowest (5 ng) or middle (50 ng) dose of GDNF tested also had no effect on NREMS, REMS, SWA, or T br . However, intracerebroventricular administration of the highest dose of GDNF (500 ng) increased the amount of time spent in NREMS by ϳ1 h over the 23-h recording period [ Fig. 2 Fig. 2 and Table 1 ).
Although not systematically quantified, GDNF did not induce abnormal behavior in either rats or rabbits in the sense that animals continued to cycle through sleep-wake episodes, they were easily aroused if disturbed, and they exhibited no gross abnormal motor behavior.
DISCUSSION
The current results clearly indicate that GDNF promotes sleep in rats and rabbits. The effects of GDNF on sleep depended on the time of administration in rats. Previously, differences in sleep responses in rats were reported after administration of sleep-promoting or sleep-inhibiting substances at different times of the day. For example, administration of 10.0 ng IL-1␤ at dark onset enhances NREMS in rats, whereas the same dose of IL-1␤ suppresses NREMS if given during the light period (26). These differences likely resulted from the interaction of the circadian and homeostatic processes regulating sleep.
GDNF failed to enhance EEG delta wave activity during NREMS. In contrast, several other somnogenic growth factors, such as IL-1␤, TNF-␣, GHRH, and aFGF, enhance EEG SWA at doses that also enhance duration of NREMS. The mechanisms responsible for EEG SWA remain unknown. In many circumstances, EEG SWA is thought to be indicative of NREMS intensity. For example, after sleep deprivation, "supranormal" EEG slow waves characterize NREMS (28) and are associated with higher arousal thresholds (27) . Nevertheless, there is an extensive literature describing the separation of EEG SWA from state regulation.
For instance, intraperitoneal injections of IL-1␤ or TNF-␣ induce increases in NREMS and decreases in EEG SWA in rats (7) and mice (4), whereas intracerebroventricular injections of IL-1 or TNF enhance both of these of parameters (8, 26) . Electrolytic lesions of the hypothalamus result in long-term reduction of EEG SWA, whereas NREMS moves toward normal duration after ϳ8 days (32) . Furthermore, rats restricted to a daytime diet shift their diurnal rhythm of NREMS, becoming daytime active, but do not shift the diurnal rhythm of EEG SWA (30) . Regardless of such considerations, it does not appear that GDNF has a major role in the regulation of EEG SWA, although it has the capacity to enhance NREMS, thereby suggesting that the mechanisms responsible for EEG SWA are different, in part, from those involved in sleep regulation.
The significance of the GDNF-induced inhibition of REMS in rabbits after the high dose is unknown. The mechanisms responsible for REMS regulation are, in part, independent from those responsible for NREMS (reviewed in Ref. 14) , and it is possible to differentially stimulate or inhibit NREMS or REMS (e.g., see Table  1 ). Nevertheless, one possible mechanism of GDNF inhibition of REMS could be via dopaminergic neurons. GDNF is dopaminotrophic (2, 23) , and dopaminergic neurons are implicated in sleep regulation (35) . For instance, dopamine autoreceptor antagonists inhibit REMS (24) . Furthermore, GFR␣-1 receptors are in many areas of brain, including the cholinergic system (22) , which is also implicated in REMS regulation (reviewed in Ref. 33) . Regardless, the effects of GDNF on REMS were small and only occurred in one species after the highest dose; thus, it remains to be determined whether this effect has biological significance.
The biological significance of the enhanced T br in rats after GDNF is also questionable since rabbits, a species often considered more sensitive to pyrogens, failed to display fever after GDNF. In rats, GDNF induced very small increases in T br , and it is possible that the hyperthermia affected sleep responses. Regardless, there is a rather extensive literature describing the multiple links between thermoregulation and sleep. For example, there is a regulated decrease in T br during the entry into NREMS, and an acute mild increase in ambient temperature is a well-characterized somnogen. Nevertheless, under a variety of circumstances, thermoregulation can be separated from sleep regulation (reviewed in Ref. 16 ). Some substances enhance both NREMS and T br (e.g., TNF and IL-1␤), yet the pyrogenic actions of IL-1␤ can be pharmacologically blocked without affecting sleep responses (17) . In contrast, the NREMS-promoting actions of IL-1␤, but not its pyrogenic actions, are blocked by central administration of nitric oxide synthase inhibitors (9) . Furthermore, some substances (e.g., IL-6) are pyrogenic but not somnogenic (25) . Collectively, such considerations clearly indicate separate, yet linked, mechanisms for sleep and body temperature.
Microbial products such as endotoxin are common contaminants of manufactured peptides (21) . Endotoxin induces production of a variety of somnogenic cytokines, and it is, itself, somnogenic. We thus tested heat-inactivated GDNF as a control, since endotoxin and other pyrogenic bacterial cell wall products are heat stable. Because the heat-inactivated GDNF had no effect on the sleep parameters studied, it seems unlikely that results obtained were due to contaminating bacterial cell wall products.
Perspectives
That GDNF promotes NREMS provides further evidence for the involvement of the brain cytokine network in sleep regulation. Previously, we hypothesized that cytokines and other somnogenic growth factors are important components of sleep mechanisms and are indicative of, and play a role in, sleep function (reviewed in Ref. 12 ). Thus we proposed that neuronal activation stimulates production of these sleep regulatory growth factors, e.g., GDNF mRNA levels are enhanced by neuron excitation (29) . These growth factors alter membrane potentials of nearby neurons and thereby change their firing patterns. Thus synapses that were not activated by the initial train of events are secondarily activated with a time delay due to the production and diffusion times of upregulated growth factors (modeled in Ref. 13) . As a consequence, the input-output activity patterns of neuronal groups are changed and thereby divorce environmental input from output; when this occurs, we hypothesize that the neuronal groups are in a state of sleep. Kavanau (10) also reached the conclusion that neuronal groups alter between states, although he used different reasoning. Finally, these growth factors also alter expression of genes involved in synaptic function. As a consequence, the efficacy of transmission at affected synapses is changed for longer periods of time because of structural changes. Thus sleep function (growth factor-induced synaptic sculpturing) is inseparable from sleep mechanisms (growth factor-induced altered circuit dynamics of neuronal groups; reviewed in Ref. 15 ).
